ArticleFrontiers in immunology2025
Intravital imaging reveals spatiotemporal dynamics of oncolytic
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oncolytic bacteria therapy for malignant glioma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In recent years, oncolytic bacterial therapy has emerged as a promising strategy in cancer research due to its unique advantages in tumor targeting and immune activation. Among various bacterial candidates, Methods: A dorsal skin-fold window chamber model was established in nude mice bearing tdTomato-labeled MDA-MB-231 xenografts. Real-time intravital imaging was used to track tumor growth, angiogenesis, and EGFP-labeled YB1 distribution after intravenous administration. Results: Following intravenous injection, YB1 was retained in local vascular regions within the characteristically disordered tumor vascular network, such as "Shoulder Structure" or "Maze Structure". This physical entrapment facilitated direct interaction between YB1 and vascular endothelial cells, leading to endothelial damage and subsequent intratumoral vascular thrombosis. This process effectively blocked the tumor's blood supply and induced local hypoxia. Importantly, the formation of thrombosis and the hypoxic microenvironment further promoted the colonization and proliferation of YB1 within the tumor parenchyma, ultimately achieving effective tumor targeting and regression. Discussion: This study reveals the novel mechanism of YB1's tumor targeting and colonization from the perspective of interaction with tumor vasculature. These findings providing critical theoretical support for the future design of more efficient and safer oncolytic bacterial therapies and lay a foundation for YB1's clinical optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.